Literature DB >> 14673512

Further characterization of the 5-HT1 receptors mediating cardiac sympatho-inhibition in pithed rats: pharmacological correlation with the 5-HT1B and 5-HT1D subtypes.

Araceli Sánchez-López1, David Centurión, Erika Vázquez, Udayasankar Arulmani, Pramod R Saxena, Carlos M Villalón.   

Abstract

Serotonin (5-hydroxytryptamine; 5-HT) is capable of inhibiting the tachycardic responses elicited by sympathetic stimulation, but not by exogenous noradrenaline, in pithed rats pre-treated with desipramine. More recently, it has been shown that this cardiac sympatho-inhibitory response to 5-HT, mediated by prejunctional 5-HT1 receptors as well as putative 5-ht5A/5B receptors, is mimicked dose-dependently by the agonists CP 93,129 (r5-HT1B), sumatriptan (5-HT1B/1D) and PNU-142633 (5-HT1D). This study analysed further the pharmacological profile of the above 5-HT1 receptors. Continuous i.v. infusions of CP 93,129, sumatriptan or PNU-142633 (30 micro g kg(-1)min(-1) each) failed to modify the tachycardic responses to exogenous noradrenaline but inhibited those elicited by preganglionic (C7-T1) stimulation of the cardiac sympathetic outflow. These sympatho-inhibitory responses were unaltered after i.v. administration of physiological saline (1 ml kg(-1)) or the 5-HT1A receptor antagonist WAY 100635 (10 micro g kg(-1)). In contrast, the antagonist GR 127935 (5-HT1B/1D; 100 micro g kg(-1), i.v.) abolished the responses to CP 93,129, sumatriptan and PNU-142633, whilst SB224289 (5-HT1B; 300 micro g kg(-1), i.v.) abolished the responses to CP 93,129 without affecting those to sumatriptan and PNU-142633. Interestingly, BRL15572 (5-HT1D; 300 micro g kg(-1), i.v.) abolished the responses to PNU-142633 and attenuated those to sumatriptan, but not those to CP 93,129. WAY 100635, GR 127935, SB224289 and BRL15572, given alone at the above doses, failed to modify the sympathetically induced tachycardic responses. The 5-HT1 receptors producing cardiac sympatho-inhibition in pithed rats thus display the pharmacological profile of the 5-HT1B and 5-HT1D receptor subtypes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14673512     DOI: 10.1007/s00210-003-0842-0

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  25 in total

1.  Pharmacological profile of the 5-HT-induced inhibition of cardioaccelerator sympathetic outflow in pithed rats: correlation with 5-HT1 and putative 5-ht5A/5B receptors.

Authors:  Araceli Sánchez-Lopez; David Centurión; Erika Vázquez; Udayasankar Arulmani; Pramod R Saxena; Carlos M Villalón
Journal:  Br J Pharmacol       Date:  2003-09-22       Impact factor: 8.739

2.  Isochroman-6-carboxamides as highly selective 5-HT1D agonists: potential new treatment for migraine without cardiovascular side effects.

Authors:  M D Ennis; N B Ghazal; R L Hoffman; M W Smith; S K Schlachter; C F Lawson; W B Im; J F Pregenzer; K A Svensson; R A Lewis; E D Hall; D M Sutter; L T Harris; R B McCall
Journal:  J Med Chem       Date:  1998-06-18       Impact factor: 7.446

Review 3.  GR127935: a potent and selective 5-HT1D receptor antagonist.

Authors:  M Skingle; D T Beattie; D I Scopes; S J Starkey; H E Connor; W Feniuk; M B Tyers
Journal:  Behav Brain Res       Date:  1996       Impact factor: 3.332

4.  SB-216641 and BRL-15572--compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors.

Authors:  G W Price; M J Burton; L J Collin; M Duckworth; L Gaster; M Göthert; B J Jones; C Roberts; J M Watson; D N Middlemiss
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1997-09       Impact factor: 3.000

5.  5-Hydroxytryptamine inhibits the tachycardia induced by selective preganglionic sympathetic stimulation in pithed rats.

Authors:  C M Villalón; D Centurión; M del Mar Fernández; A Morán; A Sánchez-López
Journal:  Life Sci       Date:  1999       Impact factor: 5.037

6.  Differential pharmacology between the guinea-pig and the gorilla 5-HT1D receptor as probed with isochromans (5-HT1D-selective ligands).

Authors:  J F Pregenzer; G L Alberts; W B Im; J L Slightom; M D Ennis; R L Hoffman; N B Ghazal; R E TenBrink
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

7.  Pharmacological characterization of 5-hydroxytryptamine-induced hyperpolarization of the rat superior cervical ganglion.

Authors:  S J Ireland; C C Jordan
Journal:  Br J Pharmacol       Date:  1987-10       Impact factor: 8.739

Review 8.  International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin).

Authors:  D Hoyer; D E Clarke; J R Fozard; P R Hartig; G R Martin; E J Mylecharane; P R Saxena; P P Humphrey
Journal:  Pharmacol Rev       Date:  1994-06       Impact factor: 25.468

9.  3-(1,2,5,6-Tetrahydropyrid-4-yl)pyrrolo[3,2-b]pyrid-5-one: a potent and selective serotonin (5-HT1B) agonist and rotationally restricted phenolic analogue of 5-methoxy-3-(1,2,5,6-tetrahydropyrid-4-yl)indole.

Authors:  J E Macor; C A Burkhart; J H Heym; J L Ives; L A Lebel; M E Newman; J A Nielsen; K Ryan; D W Schulz; L K Torgersen
Journal:  J Med Chem       Date:  1990-08       Impact factor: 7.446

10.  Cardiovascular response to 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) in the rat: site of action and pharmacological analysis.

Authors:  J R Fozard; A K Mir; D N Middlemiss
Journal:  J Cardiovasc Pharmacol       Date:  1987-03       Impact factor: 3.105

View more
  9 in total

1.  Fluoxetine Treatment Decreases Cardiac Vagal Input and Alters the Serotonergic Modulation of the Parasympathetic Outflow in Diabetic Rats.

Authors:  Mónica García-Domingo; José Ángel García-Pedraza; Juan Francisco Fernández-González; Cristina López; María Luisa Martín; Asunción Morán
Journal:  Int J Mol Sci       Date:  2022-05-20       Impact factor: 6.208

2.  The role of purinergic P2Y12 and P2Y13 receptors in ADPβS-induced inhibition of the cardioaccelerator sympathetic drive in pithed rats.

Authors:  Belinda Villanueva-Castillo; Eduardo Rivera-Mancilla; Kristian Agmund Haanes; Antoinette MaassenVanDenBrink; Carlos M Villalón
Journal:  Purinergic Signal       Date:  2020-02-17       Impact factor: 3.765

Review 3.  Cardiovascular responses produced by 5-hydroxytriptamine:a pharmacological update on the receptors/mechanisms involved and therapeutic implications.

Authors:  Carlos M Villalón; David Centurión
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-08-17       Impact factor: 3.000

4.  The role of dopamine D2, but not D3 or D4, receptor subtypes, in quinpirole-induced inhibition of the cardioaccelerator sympathetic outflow in pithed rats.

Authors:  A H Altamirano-Espinoza; A González-Hernández; G Manrique-Maldonado; B A Marichal-Cancino; I Ruiz-Salinas; C M Villalón
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

5.  Pharmacological characterization of ergotamine-induced inhibition of the cardioaccelerator sympathetic outflow in pithed rats.

Authors:  Luis E Cobos-Puc; Carlos M Villalón; Araceli Sánchez-López; Martha B Ramírez-Rosas; Jair Lozano-Cuenca; Heinz H Pertz; Tilo Görnemann; David Centurión
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-09-09       Impact factor: 3.000

6.  Serotonin type 1D receptors (5HTR) are differentially distributed in nerve fibres innervating craniofacial tissues.

Authors:  A M Harriott; M S Gold
Journal:  Cephalalgia       Date:  2008-06-28       Impact factor: 6.292

7.  Dihydroergotamine inhibits the vasodepressor sensory CGRPergic outflow by prejunctional activation of α2-adrenoceptors and 5-HT1 receptors.

Authors:  Abimael González-Hernández; Jair Lozano-Cuenca; Bruno A Marichal-Cancino; Antoinette MaassenVanDenBrink; Carlos M Villalón
Journal:  J Headache Pain       Date:  2018-05-25       Impact factor: 7.277

8.  Characterization of binding, functional activity, and contractile responses of the selective 5-HT1F receptor agonist lasmiditan.

Authors:  Eloísa Rubio-Beltrán; Alejandro Labastida-Ramírez; Kristian A Haanes; Antoon van den Bogaerdt; Ad J J C Bogers; Eric Zanelli; Laurent Meeus; A H Jan Danser; Michael R Gralinski; Peter B Senese; Kirk W Johnson; Joseph Kovalchin; Carlos M Villalón; Antoinette MaassenVanDenBrink
Journal:  Br J Pharmacol       Date:  2019-11-07       Impact factor: 8.739

9.  Role of peripheral 5-HT5A receptors in 5-HT-induced cardiac sympatho-inhibition in type 1 diabetic rats.

Authors:  José Ángel García-Pedraza; Oswaldo Hernández-Abreu; Asunción Morán; José Carretero; Mónica García-Domingo; Carlos M Villalón
Journal:  Sci Rep       Date:  2020-11-09       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.